3,440€
0,29%
Echtzeit-Aktienkurs Nephros
Bid:
Ask:
Echtzeit-Chart der Nephros Aktie
Börsenkurse Nephros
| USA | - | - | - | - | 3,980$ | -1,73% |
| Börse Stuttgart | - | - | - | - | 3,340€ | -2,34% |
| Echtzeit Euro | - | - | - | - | 3,440€ | 0,29% |
| Echtzeit USD | - | - | - | - | 3,987$ | -1,56% |
| Nasdaq | - | - | - | - | 3,970$ | -1,49% |
Fundamentaldaten der Nephros Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [USD] | 14,16 Mio. | 0,09 Mio. | 0,07 Mio. | 0,01 | - | 491,43 | 2,56 |
| 2023 [USD] | 14,24 Mio. | -1,58 Mio. | -1,58 Mio. | -0,15 | - | - | 2,55 |
| 2022 [USD] | 9,98 Mio. | -4,28 Mio. | -7,38 Mio. | -0,72 | - | - | 3,55 |
| 2021 [USD] | 10,40 Mio. | -3,87 Mio. | -4,11 Mio. | -0,41 | - | - | 3,39 |
| 2020 [USD] | 8,56 Mio. | -4,53 Mio. | -4,77 Mio. | -0,53 | - | - | 3,97 |
| 2019 [USD] | 10,33 Mio. | -3,40 Mio. | -3,42 Mio. | -0,45 | - | - | 2,68 |
| 2018 [USD] | 5,69 Mio. | -3,42 Mio. | -3,40 Mio. | -0,50 | - | - | 4,34 |
| 2017 [USD] | 3,81 Mio. | -2,60 Mio. | -0,81 Mio. | -0,14 | - | - | 5,55 |
| 2016 [USD] | 2,32 Mio. | -3,03 Mio. | -3,03 Mio. | -0,54 | - | - | 8,20 |
| 2015 [USD] | 1,94 Mio. | -3,09 Mio. | -3,09 Mio. | -0,81 | - | - | 9,55 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Nephros Aktie
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.